Related Experiment Videos
[Stomach carcinoma. Optimizing therapy by neoadjuvant or adjuvant therapy?]
1Chirurgische Abteilung, Donauspital, Ludwig Boltzmann-Institut für Chirurgische Onkologie, Wien.
Zentralblatt Fur Chirurgie
|July 27, 1999
Summary
Gastric cancer survival remains poor despite surgery, as late diagnosis and ineffective postoperative chemotherapy are common. Neoadjuvant chemotherapy shows promise but requires further phase III trial confirmation.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- Gastric cancer prognosis has not improved with surgery alone in Western countries.
- Late diagnosis leading to advanced tumor stage is a significant challenge.
- Postoperative chemotherapy has historically failed to improve outcomes for gastric cancer patients.
Purpose:
- To evaluate the efficacy of neoadjuvant chemotherapy combined with surgery and adjuvant therapy for potentially resectable gastric cancer.
- To address the limitations of previous studies, including small patient numbers and high locoregional relapse rates.
Summary:
- Intraperitoneal adjuvant chemotherapy demonstrated survival benefits in Asian studies and was part of successful Western phase II trials.
- Neoadjuvant therapy has shown potential for tumor downstaging in advanced gastric cancer.
- Multimodality approaches involving neoadjuvant chemotherapy are being investigated to improve gastric cancer outcomes.
Impact:
- Investigating neoadjuvant chemotherapy aims to improve survival rates for gastric cancer patients.
- Confirming efficacy in phase III trials is crucial for establishing this therapeutic approach.
- This research could lead to improved treatment strategies for advanced gastric cancer.